Hologic pacifies US Federal Trade Commission and sells Mammotest to Siemens
This article was originally published in Clinica
Hologic is to sell all intellectual property relating to its Mammotest prone stereotactic bed breast biopsy systems (SBBS), which the company had recently acquired from Fischer Imaging, to diagnostic imaging rival Siemens Medical Solutions for $6.5m. The move followed a complaint filed last week by the US Federal Trade Commission (FTC), alleging that Hologic's acquisition of Fischer's prone SBBS business gave the former a monopoly in the US market for these devices.
You may also be interested in...
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.